CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 28 - November 1, 2013 at The Moscone Center in San Francisco, California.

Clinical trial data and first report investigations presented at TCT often direct the course of patient therapies. The studies selected will shed new light on the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Tuesday, October 29; Wednesday, October 30; and Thursday, October 31.

This year, TCT will also mark 25 years of innovation with a day-long look back at the significant contributions that interventional cardiology has made to patients with cardiovascular disease, as well as an inspiring look ahead at new therapies being developed for the not too distant future.

Media are invited to attend TCT; press credentials and registration information can be found here: http://www.tctconference.com/press/press-registration-form.html

TUESDAY OCTOBER 29, 2013
Late Breaking Trials

  • SAFE-PCI: A Prospective, Registry-Based Randomized Trial of Radial Versus Femoral Vascular Access in Women Undergoing Diagnostic Cardiac Catheterization and PCI
  • COREVALVE EXTREME RISK: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Self-Expanding Transcatheter Heart Valve in Patients with Severe Aortic Stenosis
  • SORT-OUT VI: A Prospective, Randomized "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents Versus Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary Stents

WEDNESDAY, OCTOBER 30, 2013
Late Breaking Trials

  • EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin Versus Heparin - Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI Undergoing Primary PCI
  • NORDIC-BALTIC BIFURCATION IV: A Prospective, Randomized Trial of a Two-Stent Strategy Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions
  • TRYTON: A Prospective, Randomized Trial of a Dedicated Sidebranch Stent Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions

First Report Investigations

  • LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries
  • RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty Versus Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis
  • SMART-CASE: A Prospective, Randomized Trial of Conservative Revascularization Versus Aggressive Revascularization in Patients with Intermediate Lesions Undergoing PCI with Angiographic Guidance Alone
  • HeartFlowNXT: A Prospective, Registry Evaluation of Noninvasive FFRCT Versus Invasive FFR
  • ADVISE II: A Prospective, Registry Evaluation of iFR Versus FFR -CHILL-MI: A Prospective, Randomized Trial of Therapeutic Hypothermia in Patients with Acute Myocardial Infarction Undergoing Primary PCI

THURSDAY, OCTOBER 31, 2013
Late Breaking Trials

  • OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy After PCI
  • ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of 2 Years Versus 1 Year of Dual Antiplatelet Therapy After PCI
  • DUTCH PEERS (TWENTE II): A Prospective, Randomized "All-Comers" Trial of Zotarolimus-Eluting Stents Versus Everolimus-Eluting Coronary Stents

First Report Investigations

  • REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis
  • FREEDOM: A Prospective, Randomized Trial of First Generation DES Versus CABG in Insulin and Non-Insulin Treated Diabetic Patients
  • HYBRID: A Prospective, Randomized Trial of Hybrid Coronary Revascularization Versus Standard Surgical Revascularization in Multivessel Disease
  • TRANSLATE-POPS: A Prospective, Cluster-Randomized Trial of Routine Platelet Function Testing in Patients Undergoing PCI
  • GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction
  • TATORT-NSTEMI: A Prospective, Randomized Trial of Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Segment Elevation Myocardial Infarction

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Postmenopausal hormone therapy use declines amidst risk-benefit concerns